Rivastigmine for Delirium
(RIVA-AP Trial)
Trial Summary
What is the purpose of this trial?
Antimuscarinic delirium (AMD) is a common and dangerous toxicology condition caused by poisoning by medications and other chemicals that block muscarinic receptors. Physostigmine is effective in reversing AMD but has a short duration of action, and patient commonly experience recurrence of AMD after initial control with physostigmine. Recent case reports and small observational studies suggest that rivastigmine, which has a longer duration of action than physostigmine, might be useful in the treatment of AMD. In order to investigate the effectiveness of rivastigmine in preventing recurrence of AMD after initial control with physostigmine, the investigators propose a randomized, placebo-controlled clinical trial of rivastigmine for AMD. The investigators hypothesize that patients treated with rivastigmine after initial control of AMD with physostigmine will experience less recurrence of antimuscarinic delirium than those treated with placebo.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the drug Rivastigmine for treating delirium?
Research Team
Kevin Baumgartner, MD
Principal Investigator
Washington University School of Medicine
Eligibility Criteria
This trial is for patients who have experienced antimuscarinic delirium (AMD), a type of confusion and agitation caused by certain medications or poisons. Participants must have had their AMD initially controlled with physostigmine but are at risk of its recurrence.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either rivastigmine or placebo to prevent recurrence of antimuscarinic delirium after initial control with physostigmine
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Rivastigmine
Rivastigmine is already approved in European Union, United States for the following indications:
- Alzheimer's Disease
- Parkinson's Disease Dementia
- Alzheimer's Disease
- Parkinson's Disease Dementia
Find a Clinic Near You
Who Is Running the Clinical Trial?
Washington University School of Medicine
Lead Sponsor
American Academy of Clinical Toxicology
Collaborator
American Academy of Clinical Toxicology
Collaborator